Research at Friedrich-Alexander-Universität Erlangen-Nürnberg and Johannes Gutenberg Universität Mainz has led to the development of quinazoline-thiohydantoin fused heterocycles reported to be useful for the treatment of leukemia.
Senya Pharmaceuticals Inc. has patented thyroid hormone receptor beta (TR-β) agonists reported to be useful for the treatment of dyslipidemia, hypercholesterolemia, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and liver disease.
Mindset Pharma Inc. has patented indole derivatives acting as 5-HT2A receptor agonists and reported to be useful for the treatment of neurological disorders and psychosis.
Researchers at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have developed urea compounds containing 2-heteroaromatic ring substitution that act as cyclin-dependent kinase 9 (CDK9) inhibitors.
A recent Moya Bio Ltd. patent describes fused azole and furan-based nucleoside analogues acting as ubiquitin-like modifier-activating enzyme 1 (UBA1; UBE1) inhibitors and thus reported to be potentially useful for the treatment of inflammation, cancer, parasitic infections and autoimmune diseases.
Chemocentryx Inc. has described aryl sulfonyl (hydroxy) piperidines acting as C-C chemokine receptor type 6 (CCR6) antagonists reported to be useful for the treatment of atopic dermatitis, psoriasis, endometriosis, periodontitis, rheumatoid arthritis, scleroderma, psoriatic arthritis and inflammatory disorders.
Shanghai Blueray Biopharma Co. Ltd. has divulged polycomb protein EED (PRC2/EED-EZH2 noncatalytic subunit) inhibitors reported to be useful for the treatment of cancer.
RSS